An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
Advertisement
Articles by Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.
Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.
Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.
Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.
Advertisement
Latest Updated Articles
PI3KCA Inhibition: Managing AEs in HR+ mBCPublished: July 21st 2021 | Updated:
Early Stage HR+ Breast Cancer: Optimizing Multigene AssaysPublished: August 4th 2021 | Updated:
Using Genomic Assays for Early Stage HR+ Breast CancerPublished: July 28th 2021 | Updated:
ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical PracticePublished: August 11th 2021 | Updated:
Emerging Agents for the Management of HR+ mBCPublished: July 28th 2021 | Updated:
Using CDK4/6 Inhibitors After HR+ mBC Disease ProgressionPublished: July 21st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5